Valuable Targets

What are ACE2 inhibitor and how do you quickly get the latest development progress?

13 November 2023
4 min read

ACE2, or angiotensin-converting enzyme 2, is a crucial enzyme found in the human body. It plays a significant role in regulating the renin-angiotensin system, which controls blood pressure and fluid balance. ACE2 acts as a receptor for the entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the COVID-19 pandemic. By binding to ACE2, the virus gains entry into human cells, particularly in the respiratory system. Understanding the role of ACE2 is vital for developing therapeutic interventions and vaccines to combat COVID-19 and other related diseases.

Angiotensin converting enzyme (ACE2) is a homologue of carboxypeptidase ACE, which produces angiotensin II, the main active peptide of the renin-angiotensin system (RAS). After the cloning of ACE2 in 2000, three main functions of ACE2 have been described to date. ACE2 is a powerful negative regulator of RAS, which can balance various functions of ACE. By targeting angiotensin II, ACE2 shows a protective effect in the cardiovascular system and many other organs. ACE2 has been identified as the main binding receptor for both SARS coronavirus and the new coronavirus from Wuhan. In SARS, the downregulation of ACE2 plays an important role in the pathogenesis of severe lung failure after viral infection. ACE2 and its homologue Collectrin can bind to amino acid transporters and play an important role in the absorption of amino acids in the kidneys and intestines. 

How do they work?

ACE2 inhibitors are a type of medication that work by blocking the activity of the enzyme ACE2 (angiotensin-converting enzyme 2). ACE2 is an important enzyme involved in the regulation of the renin-angiotensin-aldosterone system (RAAS), which plays a role in blood pressure regulation and fluid balance in the body.

From a biomedical perspective, ACE2 inhibitors are primarily used in the treatment of cardiovascular conditions such as hypertension (high blood pressure) and heart failure. By inhibiting ACE2, these medications can help to reduce the production of angiotensin II, a hormone that constricts blood vessels and increases blood pressure. This can lead to a decrease in blood pressure and improved heart function.

In addition to their cardiovascular effects, ACE2 inhibitors have gained significant attention in the context of viral infections, particularly during the COVID-19 pandemic. ACE2 is the receptor that the SARS-CoV-2 virus (which causes COVID-19) uses to enter human cells. Some studies have suggested that ACE2 inhibitors may have a potential role in preventing or reducing viral entry into cells, although further research is needed to fully understand their efficacy and safety in this context.

List of ACE2 Inhibitors

The currently marketed ACE2 inhibitors include:

For more information, please click on the image below.

What are ACE2 inhibitors used for?

ACE2 inhibitors are used to treat cardiovascular diseases, particularly hypertension. By targeting ACE2, these inhibitors aim to potentially prevent the SARS-CoV-2 virus from entering human cells and reduce COVID-19 symptoms and complications. For more information, please click on the image below to log in and search.

How to obtain the latest development progress of ACE2 inhibitors?

In the Synapse database, you can keep abreast of the latest research and development advances of ACE2 inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面

描述已自动生成

Essential Tool in Interventional Radiology: Contrast Agent
Advanced Tech.
6 min read
Essential Tool in Interventional Radiology: Contrast Agent
13 November 2023
A Contrast agent, also known as a contrast medium, is a specific substance that is introduced into the human body for the purpose of medical imaging – it is used to alter the contrast of images of parts of the body.
Read →
Kodiak's innovative therapy, tarcocimab tedromer, reaches primary endpoint in Phase 3 trial for the treatment of diabetic retinopathy
Latest Hotspot
3 min read
Kodiak's innovative therapy, tarcocimab tedromer, reaches primary endpoint in Phase 3 trial for the treatment of diabetic retinopathy
10 November 2023
Kodiak Sciences recently revealed that its Phase III GLOW study of tarcocimab tedromer, a 5 mg ABC therapy for moderate to severe NPDR, met its primary one-year endpoint.
Read →
T-cell co-stimulation target: 4-1BB (CD137)
T-cell co-stimulation target: 4-1BB (CD137)
10 November 2023
4-1BB (also known as CD137 or TNFRSF9) was first discovered in 1989 and is a critical co-stimulation receptor on T cells and other immune cells.
Read →
Abbisko Therapeutics' FGFR4 inhibitor, ABSK012, has received FDA clinical trial approval for the treatment of advanced solid tumors
Latest Hotspot
3 min read
Abbisko Therapeutics' FGFR4 inhibitor, ABSK012, has received FDA clinical trial approval for the treatment of advanced solid tumors
10 November 2023
Abbisko Therapeutics recently reported that its self-developed small molecule FGFR4 inhibitor ABSK012, aimed at drug-resistant mutations, has received FDA approval to begin phase I human trials with advanced solid tumor patients.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.